The Current Perspectives of Stem Cell Therapy in Orthopedic Surgery by Akpancar, S. et al.
Arch Trauma Res. 2016 December; 5(4):e37976.
Published online 2016 August 16.
doi: 10.5812/atr.37976.
Review Article
The Current Perspectives of Stem Cell Therapy in Orthopedic Surgery
Serkan Akpancar,1,* Oner Tatar,2 Hasan Turgut,3 Faruk Akyildiz,1 and Safak Ekinci4
1Department of Orthopedic Surgery, Gulhane Military Hospital, Ankara, Turkey
2Department of Orthopedic Surgery, Air Force Academy Kasımpa¸sa Military Hospital, Istanbul, Turkey
3Department of Orthopedic Surgery, Bursa Military Hospital, Bursa, Turkey
4Department of Orthopedic Surgery, Agri Military Hospital, Agri, Turkey
*Corresponding author: Serkan Akpancar, Department of Orthopedic Surgery, Gulhane Military Medicine Academy, Ankara, Turkey. Tel: +90-5443229700, Fax: +90-3124045500,
E-mail: drserkanakpancar@gmail.com
Received 2016 April 07; Revised 2016 June 16; Accepted 2016 June 23.
Abstract
Context: Musculoskeletal injuries may be painful, troublesome, life limiting and also one of the global health problems. There has
been considerable amount of interest during the past two decades to stem cells and tissue engineering techniques in orthopedic
surgery, especially to manage special and compulsive injuries within the musculoskeletal system.
Evidence Acquisition: The aim of this study was to present a literature review regarding the most recent progress in stem cell
procedures and current indications in orthopedics clinical care practice. The Medline and PubMed library databases were searched
for the articles related with stem cell procedures in the field of orthopedic surgery and additionally the reference list of each article
was also included to provide a comprehensive evaluation.
Results: Various sources of stem cells have been studied for orthopedics clinical care practice. Stem cell therapy has success-
fully used for major orthopedic procedures in terms of bone-joint injuries (fractures-bone defects, nonunion, and spinal injuries),
osteoarthritis-cartilage defects, ligament-tendon injuries, femoral head osteonecrosis and osteogenesis imperfecta. Stem cells have
also used in bone tissue engineering in combining with the scaffolds and provided faster and better healing of tissues.
Conclusions: Large amounts of preclinical studies have been made of stem cells and there is an increasing interest to perform these
studies within the human population but preclinical studies are insufficient; therefore, much more and efficient studies should be
conducted to evaluate the efficacy and safety of stem cells.
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1. Context
Musculoskeletal injuries may be painful, troublesome,
life limiting and also one of the global health problems.
Various treatment modalities are available for treating
these problems; however, the most effective method is con-
troversial (1-3). Current research has focused on identifying
novel and effective methods of addressing the morbidity
associated with musculoskeletal injuries. Stem cells are a
promising and growing area of researches within the med-
ical field (4).
Stem cells are described as to have a potential to dif-
ferentiate more than 200 different cell types in the body.
They are specific cell types that can create new cells in exist-
ing healthy tissues and may help to repair tissues in those
structures that are injured or damaged when they differen-
tiate into multi lineages and becoming multipotent under
appropriate conditions (5). They primarily create progeni-
tor cells and these cells have capability of more specialized
functions, such as brain cells, red blood cells, bone or carti-
lage (2). Among the different sources for cell therapy, mes-
enchymal stem cells (MSCs) are the most preferred source
because they can differentiate to many different tissues, in
terms of muscles, bones, fat and cartilage (6), and can be
obtained from many sources, such as bone, tendon, skin,
adipose tissue, umbilical cord, blood and amnion (7-11).
Over the past 15 years, orthopedic surgeons have fo-
cused their attention to MSCs therapies (12, 13). There are
plenty of animal studies that have successful results and
there is an increasing concern about their use in human
studies6. In these studies, stem cell procedures have been
focused on promoting fracture healing and nonunion, re-
generating articular cartilage in degenerated joints, heal-
ing ligaments or tendon injuries, and replacing degenera-
tive vertebral disks (6).
2. Evidence Acquisition
The aim of this study was to present a literature re-
view regarding the most recent progress in stem cell proce-
dures and current indications in orthopedics clinical care
practice. The inclusion criteria for this review were all the
study types related with orthopedics surgery and stem cell
therapy. Studies evaluating different methods, and stem
cell procedures nonrelated with orthopedic surgery were
excluded. The Medline and PubMed library databases (1946
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to the 15th of December 2015) were searched for the articles
related with stem cell procedures in the field of orthopedic
surgery and additionally the reference list of each article
was also included to provide a comprehensive evaluation.
3. Results
3.1. Types of Stem Cells
3.1.1. Embryonic Stem Cells
James Thompson firstly described embryonic stem
cells in 1988 (14). These cells can be obtained from blas-
tocysts during in-vitro fertilization especially on the fifth
days of fetal life, and they are characterized as pluripotent
cells. They can be proliferated easily in the cell culture, and
differentiate into every different cell type, and thus con-
trolling stem cell growth and differentiation is difficult.
Embryonic stem cells are usually preferred for transplan-
tation, but the rejection risk is higher. Only a limited num-
ber of animal studies have been conducted on embryonic
stem cells.
3.1.2. Mature Stem Cells
Mature stem cells were described in the 1960’s. They
can be obtained from body tissues, the umbilical cord or
placenta after birth and they are characterized as multipo-
tent cells. In this type of stem cells, differentiating is lim-
ited and these cells are similar to the cells from which they
originate. They are not perceived as foreign by the immune
system. Tissue and organ regeneration and repair are en-
hanced by these cells.
Stem cells are also classified into 4 types according
to differentiating potential; totipotent cells are only be
present in early embryo, pluripotent cells can differentiate
to every cells, multipotent cells can differentiate to limited
number of cells and unipotent cells are the mature form
(15) (Figure 1).
3.2. Stem Cell Procedures in Orthopedic Surgery
Stem cell therapy has recently become popular in or-
thopedics surgery, especially in the musculoskeletal in-
juries. Musculoskeletal injuries can involve tendons and
ligaments, bone, the meniscus and cartilage. When not
treated properly, patients can have long-lasting symp-
toms such as large bone defects, pseudoarthrosis and
nonunions (16, 17).
Therapeutic applications can be performed using stem
cells as progenitor cells, and they are primarily aspired
from bone marrow then injected directly into tissues to
enhance the repair process. Mesenchymal stem cells that
are obtained from bone marrow have chondrogenic, os-
teogenic and radiogenic potentials (18). After differentia-
tion to mesenchymal progenitor cells, these cells support
to bone formation by osteogenesis; adipose tissue by adi-
pogenesis; cartilage formation by chondrogenesis; muscle
formation by myogenesis; tendon/ligament formation by
tendo/ligamentogenesis; and neuron-like cell formation
by neurogenesis.
Many sources of stem cells have been studied for or-
thopedic procedures; however, the optimal source of stem
cells has not yet been clearly defined (Figure 2).
3.2.1. Sources of Stem Cells Used for Orthopedic Procedures
3.2.1.1. Bone Marrow Derived Mesenchymal Stem Cells (BM-
MSCs)
Bone is the most common used stem cell source that
can differentiate into musculoskeletal system cells (trabec-
ular bone, tendon, articular cartilage, ligaments) in the
suitable environment as an origin of multipotent cells (19,
20). However, bone marrow aspiration can be painful, and
various complications have been stated by many authors
(21).
3.2.1.2. Adipose Derived Stem Cells (AD-MSCs)
Adipose tissue has recently described as a reliable
source for MSCs (22, 23). The procedure is less invasively as a
lipo-aspiration (24, 25). Recent studies have shown that AD-
MSCs have a considerable potential for proliferation, and
maximal strength to serum deprivation-induced apopto-
sis (26, 27).
3.2.1.3. Synovial Tissue-Derived Stem Cells (ST-MSC)
Synovial tissue is another source of stem cells used for
orthopedic procedures (28). There are few studies available
in the literature about synovial tissue-derived stem cells.
Many of them have reported better outcomes in the func-
tional scores, pain and patient satisfaction in especially
cartilage repair procedures (29).
3.2.1.4. Peripheral Blood-Derived Progenitor Cells
MSCs can be also prepared from peripheral blood. Au-
tomated cell separator (apheresis) used in this procedure
for collecting progenitor cells. The first two clinical studies
were published in 2011 by Saw et al. (30). Both of the studies
demonstrated successful results in the treatment of regen-
erated cartilage. In the histological evaluation, proteogly-
can and type II collagen proportion was substantially in-
creased and achieved 95% of the normal articular cartilage
score (31).
3.2.1.5. Bone Marrow Concentrate
This procedure was proposed by Buda et al. (32) and
Gobbi et al. (33) and the iliac crest is used for this tech-
nique. Bone marrow is aspirated and then centrifuged.
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Figure 2. Mesenchymal Stem Cell Sources and the Most Preferred Conditions in Or-
thopedic Surgery
Both of the studies reported satisfactory clinical results, es-
pecially in cartilage regeneration.
AD-MSCs and BM-MSCs have been most preferred
sources of MSCs; however, there is a controversy about the
most effective source of MSCs for orthopedic procedures
(34). Joseph et al. (35) comprised human cortical bone
fraction (CBF-MSCs), BM-MSCs and AD-MSCs, and declared
that CBF-MSCs’s osteogenic potential was superior to BM-
MSCs and AD-MSCs in normoxia and hypoxia. Veriter et al.
(36) used AD-MCSs in 11 patients with bone nonunion and 7
patients of nonhealing chronic wounds and obtained suc-
cessful results in both of the situations and did not face
with serious side effects or adverse events.
3.3. Stem Cells in Bone Tissue Engineering Studies
In light of the previous studies, stem cells have been
used in bone tissue engineering. Bone tissue engineer-
ing promises alternative tools that develop a microenvi-
ronment that holds osteogenic, osteoinductive and osteo-
conductive properties. In the recent studies, researchers
have developed strategies of combined use of MSCs and
three-dimensional biodegradable polymeric scaf-folds. In
addition, Udehiya et al. (37) declared that combined use
of hydroxyapatite scaffolds and BM-MSCs provides faster
and better healing of bone segmental defects in a rabbit
model, when compared to hydroxyapatite alone. Muwan
Chen et al. (38) declared that in vitro bone marrow human
mesenchymal stem cells that combined with hyaluronic
acid and b-Tri calcium phosphate-coated polymeric scaf-
fold provided enhanced osteogenic differentiation and cel-
lular proliferation and reorganization of the cellular ma-
trix.
Colosimo et al. (39) isolated BM-MCSs from 8 New
Zealand white adult rabbits than combined scaffold-BM-
MSCs and compared to cells cultured in absence of scaf-
folds. They obtained promising results for bone marrow
regeneration in vitro and in vivo settings. There are a few
studies available in the literature in this area; therefore,
further studies are needed to investigate the most efficient
cell-scaffold combination approach.
3.4. Orthopedic Indications of Stem Cells (Table 1)
3.4.1. Bone-Joint Injuries
Bone fractures and trauma-related joint injuries are
the primary issue of orthopedic surgery and account for
a large number of surgical procedures. The management
and treatment methods have developed in consistent with
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the increasing number of scientific researches and tech-
nological possibilities, thus patient satisfaction, and qual-
ity of regenerated tissue have increased, and recovery
time and treatment related complications have decreased.
Nonetheless, complications such as non-union, delayed
union, pseudoarthrosis, infections, loss of range of mo-
tion, and articular damage and bone defects have been
continued; therefore, there is a need for new techniques
that fasten fracture healing especially in the patients with
comorbidities or complicated fractures. Recently stem cell
procedures have investigated in the field of orthopedics to
deal such these problems and successful results were ob-
tained.
3.4.1.1. Fractures-Bone Defects
After high-energy trauma or gunshot injuries, bone de-
fects may occur from extrusion of bony fragments. Bone
defects are one of the major challenging situations of or-
thopedic surgery. In this area, the first stem cell study was
performed by Masquelet (40, 41) and then by Henrich et
al. (42), they used membranes that contain MSCs for the
femoral defects, and declared vascular endothelial growth
factor, BMP-2, TGFβ and were significantly elevated in the
membranes. This raises the question of whether BMDSCs
can be used to repair bone defects. Lio et al. (43) investi-
gated the results of preclinical studies that used BMDSCs
(bone marrow derived stem cells) for fracture healing in
their systematic review, and stated that BMDSCs enhance
bone formation and increase bone mineral density.
3.4.1.2. Nonunion
In ABD 6.2 million fractures occurred per year and 5%
- 10% of them resulted as nonunion. This is one of the
devastating problems and accounts for higher rates of pa-
tient morbidity and mortality (44, 45). There is an in-
creasing concern about stem cell studies in this area and
successful results have been reported. Bajada et al (46).
used BM-MCSs and a calcium sulphate to a patient with
tibial nonunion. His fracture was refectory to other treat-
ments and he underwent 6 previous unsuccessful opera-
tions. They declared complete union in a short time period
with BM-MCSs and a calcium sulphate (46). Giannotti et al.
(47) used BMDSCs for nonunion of long bones of 7 patients
and obtained successful results. Grgurevic et al. (48) stated
that combined BMDSCs and BMP1-3 increase type-I collagen
and osteocalcin in the nonunion of rat long bones.
3.4.1.3. Spinal Injuries
Traumatic spinal cord injury is one of the most com-
mon reasons of severe neurological damage and recovery
rates are very low (49). Recently, stem cells have been con-
ducted for axonal regeneration. Sykova et al. (49) per-
formed BMDSCs for 20 patients whom had spinal cord in-
jury and declared beneficial outcomes with this method.
Ya-jing Zhou et al. (50) used bone marrow mesenchymal
stem cell transplantation in combination with propofol
for spinal cord injury of rats and stated that the effective-
ness of bone marrow mesenchymal stem cell transplan-
tation increased with propofol in the treatment of spinal
cord injury in rats.
3.4.2. Osteoarthritis-Cartilage Defects
Osteoarthritis is the debilitating, degenerative joint
disorder. The disease commonly affects the weight bear-
ing joints, formed 40%-60% of the musculoskeletal disor-
ders (51-53). In the early stages of the disease, the joint car-
tilage is degenerated and joint space become narrow thus
affects the patient comfort and physical activity. Recently,
stem cell studies have obtained promising results in this
area and provided remarkable regeneration of joint carti-
lage and became a considerable alternative of the nonsur-
gical options (54, 55).
3.4.2.1. Cartilage Defects
Regeneration capacity of damaged hyaline cartilage is
very limited; therefore, some materials are needed for ef-
ficient and faster repair. Mesenchymal cells are the novel
methods and many authors have recommended them be-
cause they have a reliable and reproducible effect on car-
tilage repair recently. Human bone marrow stem cells
(hMSCs) have shown to have chondrogenic and regenera-
tive potential in the considerable number of studies (54-
56). Mesenchymal stem cells have a potential to produce a
cartilage-like tissue with a matrix based on type II collagen
and aggrecan under suitable culture conditions (57, 58).
In the clinical practice, isolated chondrocytes have been
prepared from healthy cartilage tissue and cultured with
the cell culture and then, they intra-articularly injected to
knees.
Wakitani firstly reported clinical application of MSCs
in the treatment of osteoarthritic knees and declared bet-
ter arthroscopic and histological outcomes (59). Mur-
doch et al. (60) stated that cultured human bone marrow
mesenchymal stem cells with Transwell permeable mem-
branes as specific growth and a differentiation factor, pro-
vided rigid translucent cartilaginous discs and expressed
cartilage-specific structural proteins as aggrecan and type
II collagen. Zhu et al. (61) preferred the combination of
BM-MCSs and a connective tissue growth factor, and they
stated that the regenerated hyaline cartilage was similar to
normal hyaline cartilage after the treatment. Guo et al. (62)
used BM-MSCs combined with TGF-beta in the treatment
4 Arch Trauma Res. 2016; 5(4):e37976.
Akpancar S et al.
Table 1. Major Orthopedic Indications of Stem Cells
Major Orthopedic Problems
Bone-Joint Injuries Osteoarthritis-Cartilage Defects Ligament-Tendon Injuries Other Conditions
Fractures-Bone defects Cartilage Defects Rotator cuff lesions Meniscopathy
Nonunion Osteoarthritis Anterior cruciate ligament lesions Femoral Head Osteonecrosis
Spinal I˙njuries Achilles Tendon Rupture Osteogenesis Imperfecta
MCL Lesions
of full-thickness defects of articular cartilage and declared
successful results. Reyes et al. (63) stated that BMDSCs com-
bined with BMP had successful results in the repair of rab-
bit’s osteochondral defects.
3.4.3. Ligament-Tendon Injuries
A nearly half of the musculoskeletal injuries involve
soft tissue injuries such as ligaments or tendons (64). Com-
plete ligament and tendon healing require a wider period
of time up to 1 to 2.5 years postinjury and the healed tis-
sue may have less organized collagen fibrils that resulted
in decreased mechanical strength; therefore, re-injury and
re-rupture risks are increased (65-68).
In general, most of the authors have stated that stem
cell therapy fasten and improve ligament-tendon heal-
ing; however, some literatures have contradictory results
(69-71). Saether et al. (72) stated that MSCs can provide
improved healing of ligament-tendon injuries. However,
lower doses of MCSs are more efficient to improve healing
when compared to higher doses. In this area stem cell stud-
ies were lower and have contradictory results. So, there is
a need for continued research to optimize stem cell proto-
cols, enhance beneficial outcomes and reduce the risk of
re-injury.
3.4.3.1. Rotator Cuff Lesions
Rotator cuff lesions are very common in the adults and
elderly. Patients are often subjected to rotator cuff injury
at a rate of 58% after shoulder trauma (73, 74). Tears within
the rotator cuff are associated with muscle pathology, such
as weakness or impingement (75). The ruptures success-
fully treated with open or arthroscopic techniques; how-
ever, re-rupture rates were high (76, 77). Yokoya et al. (78)
treated infraspinatus lesions of the rats with polyglycolic
acid combined with BM-MCSs or isolated polyglycolic acid.
They determined successful results in the combined group
when compared to the isolated group.
3.4.3.2. Anterior Cruciate Ligament Lesions
Knee injuries are very common and 17%-61% of them re-
quired surgical repair (79). Mesenchymal stem cells and
ACL fibroblasts are determined to have regenerative effects
on anterior cruciate ligament lesions (80).
3.4.3.3. Achilles Tendon Rupture
Achilles tendon ruptures are common in adults.
Adams et al. (81) compared the effectiveness of sutures
with BMDSCs and without BMDSCs on histological and
mechanical strength in the treatment of Achilles rup-
tures of rats, and stated that sutures with BMDSCs had
significantly better results than sutures without BMDSCs.
3.4.3.4. Medial Collateral Ligament Lesions
Saether et al. (69) evaluated the effectiveness of MCSs
in the treatment of medial collateral ligament (MCL) injury
of rats and stated that primed MSCs resulted in less inflam-
mation and provides high quality of healing in the short
time period.
3.4.4. Other Conditions
3.4.4.1. Meniscopathy
Meniscopathies are common in every age group. In
the progressive stages of meniscopathies, biomechanics of
knee deteriorate, and if it is not properly treated eventu-
ally osteoarthritic changes occur in the knee joint. Hat-
sushika et al. (82) performed BM-MSCs to the porcine mas-
sive meniscus defect model and evaluated with MRI and
stated that BM-MSCs can promote meniscus regeneration.
3.4.4.2. Femoral Head Osteonecrosis
It is one of the progressive diseases that commonly
seen in the younger adults by disruption of femoral head
nutrition and joint degeneration. Papakostidis et al. (83)
comprised the results of core decompression and local
MSC in treatment of femoral head avascular necrosis and
found that MSC therapy decreases the requirement of total
knee arthroplasty in the patents with femoral head AVN.
3.4.4.3. Osteogenesis Imperfecta
It is one of the genetic disorders of mesenchymal cells
and characterized by generalized osteopenia, bone defor-
mity and fractures. Complete cure is impossible with the
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current treatment methods. Horwitz et al. (84) stated that
bone mineral density increased and long-term fractures
were decreased in the patients with osteogenesis imper-
fecta with the treatment of BM-MSCs.
4. Conclusions
There has been considerable amount of interest dur-
ing the past two decades to stem cells and tissue engi-
neering techniques in orthopedic surgery, especially to
manage special and compulsive injuries within the mus-
culoskeletal system. Large amounts of preclinical studies
have been made of stem cells and there is an increasing in-
terest to perform these studies within the human popula-
tion but preclinical studies are insufficient, thus more re-
search should be conducted to evaluate the safety and effi-
cacy of stem cells.
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